{"id":17587,"date":"2025-02-03T19:19:52","date_gmt":"2025-02-03T12:19:52","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=17587"},"modified":"2025-02-03T19:19:52","modified_gmt":"2025-02-03T12:19:52","slug":"nona-biosciences-announces-strategic-collaboration-with-invetx-for-next-generation-animal-health-biotherapeutics-discovery","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=17587","title":{"rendered":"Nona Biosciences Announces Strategic Collaboration with Invetx for Next-Generation Animal Health Biotherapeutics Discovery"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

CAMBRIDGE, Mass.<\/span><\/span>, Feb. 3, 2025<\/span><\/span> \/PRNewswire\/ — Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM<\/sup>), announced today that it has entered into a strategic collaboration with Invetx, Inc. (“Invetx”), a Boston<\/span>-based animal biotechnology company, to develop next-generation animal health biotherapeutics using Nona’s HCAb Harbour Mice\u00ae<\/sup> platform.<\/p>\n

\n<\/div>\n

Nona Biosciences’\u00a0proprietary Harbour Mice\u00ae<\/sup> platform generates\u00a0monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats. The HCAb Harbour Mice\u00ae<\/sup> platform\u00a0is revolutionizing antibody development by producing unique heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering significant advantages for next-generation antibody therapies. The technology is clinically validated, globally patent protected, and worldwide endorsed and recognized.<\/p>\n

Jingsong Wang<\/span>, MD, PhD, Chairman of Nona Biosciences,\u00a0commented: “This collaboration marks an important milestone as we expand our business into the animal health sector for the first time, demonstrating the flexibility and broad application of our Harbour Mice\u00ae<\/sup>\u00a0technology. By leveraging our innovative platform, we aim to empower Invetx in advancing novel therapeutics that address critical needs in animal health.”<\/p>\n

Juergen Horn<\/span>, DVM, PhD, President of Invetx,\u00a0added, “We are excited to partner with Nona as we continue our work to create novel, protein-based animal health therapeutics. By leveraging Nona’s HCAbs, we are accelerating the development of our clinical program to demonstrate the safety and efficacy of our differentiated technology platforms.”<\/p>\n

About Nona Biosciences<\/b><\/p>\n

Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from “Idea to IND” (I to ITM<\/sup><\/span>), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice\u00ae<\/sup> platforms and the experienced therapeutic antibody discovery team.<\/p>\n

Harbour Mice\u00ae<\/sup> generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format<\/span>. Integrating Harbour Mice\u00ae<\/sup> and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit:\u00a0www.nonabio.com<\/a>.<\/p>\n

About Invetx, Inc. <\/b><\/p>\n

Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. The company leverages a best-in-class, fully integrated biotechnology platform for the discovery, development, and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in companion animals. Invetx was acquired by Dechra Pharmaceuticals Limited, a global specialist veterinary pharmaceuticals business, in July 2024<\/span>. Invetx is headquartered in Boston, Massachusetts<\/span>. For more information, see www.invetx.com<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

CAMBRIDGE, Mass.<\/span><\/span>, Feb. 3, 2025<\/span><\/span> \/PRNewswire\/ — Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM<\/sup>), announced today that it has entered into a strategic collaboration with Invetx, Inc. (“Invetx”), a Boston<\/span>-based animal biotechnology company, to develop next-generation animal health biotherapeutics using Nona’s HCAb Harbour Mice\u00ae<\/sup> platform.<\/p>\n

\n<\/div>\n

Nona Biosciences’\u00a0proprietary Harbour Mice\u00ae<\/sup> platform generates\u00a0monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats. The HCAb Harbour Mice\u00ae<\/sup> platform\u00a0is revolutionizing antibody development by producing unique heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering significant advantages for next-generation antibody therapies. The technology is clinically validated, globally patent protected, and worldwide endorsed and recognized.<\/p>\n

Jingsong Wang<\/span>, MD, PhD, Chairman of Nona Biosciences,\u00a0commented: “This collaboration marks an important milestone as we expand our business into the animal health sector for the first time, demonstrating the flexibility and broad application of our Harbour Mice\u00ae<\/sup>\u00a0technology. By leveraging our innovative platform, we aim to empower Invetx in advancing novel therapeutics that address critical needs in animal health.”<\/p>\n

Juergen Horn<\/span>, DVM, PhD, President of Invetx,\u00a0added, “We are excited to partner with Nona as we continue our work to create novel, protein-based animal health therapeutics. By leveraging Nona’s HCAbs, we are accelerating the development of our clinical program to demonstrate the safety and efficacy of our differentiated technology platforms.”<\/p>\n

About Nona Biosciences<\/b><\/p>\n

Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from “Idea to IND” (I to ITM<\/sup><\/span>), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice\u00ae<\/sup> platforms and the experienced therapeutic antibody discovery team.<\/p>\n

Harbour Mice\u00ae<\/sup> generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format<\/span>. Integrating Harbour Mice\u00ae<\/sup> and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit:\u00a0www.nonabio.com<\/a>.<\/p>\n

About Invetx, Inc. <\/b><\/p>\n

Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. The company leverages a best-in-class, fully integrated biotechnology platform for the discovery, development, and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in companion animals. Invetx was acquired by Dechra Pharmaceuticals Limited, a global specialist veterinary pharmaceuticals business, in July 2024<\/span>. Invetx is headquartered in Boston, Massachusetts<\/span>. For more information, see www.invetx.com<\/a>.<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-17587","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/17587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17587"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/17587\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17587"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17587"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}